Navigation Links
MedImmune to Present Five Abstracts on RSV at Pediatric Academic Societies Annual Meeting
Date:5/3/2010

GAITHERSBURG, Md., May 3 /PRNewswire/ -- MedImmune, the global biologics unit of AstraZeneca, announced today that researchers will present results from five studies in the areas of respiratory syncytial virus (RSV) at the 2010 Pediatric Academic Societies (PAS) annual meeting taking place May 1-4, 2010 in Vancouver, BC, Canada.  

MedImmune abstracts to be presented at PAS regarding RSV include:

  • Respiratory syncytial virus (RSV) Hospitalization in infants with Chronic Lung Disease (CLD): An eight- year retrospective national hospital survey Groothuis, J., et al; Poster Session:  May 3, 2010 Time: 4:00 PM7:30 PM; Exhibit Hall C (Vancouver Convention Centre) / Poster Presentation #353

  • Recurrent wheezing in the third year of life among children born at 32-weeks gestation: relationship to laboratory-confirmed, medically attended infection with respiratory syncytial virus (RSV) during the first year of life, Escobar G., et al; Poster Session:  May 2, 2010 Time:  4:00 PM - 7:30 PM; Exhibit Hall C (Vancouver Convention Centre) / Poster Presentation # 562.

  • A randomized controlled trial of RSV prophylaxis with motavizumab vs. palivizumab in young children with hemodynamically significant congenital heart disease (CHD).  Feltes, T., et al; Poster Session: May 3, 2010 Time:  4:00 PM - 7:30 PM; Exhibit Hall C (Vancouver Convention Centre) / Poster Presentation # 104.

  • Characterization of Respiratory Syncytial Virus (RSV) from patients who failed immunoprophylaxis with motavizumab. Zhu, Q., et al; Poster Session: May 2, 2010 Time:  4:00 PM - 7:30 PM; Exhibit Hall C (Vancouver Convention Centre) / Poster Presentation # 563.

  • Population pharmacokinetics analysis of Motavizumab in children at risk for RSV infection. Zhao, L., et al; Poster Session: May 2, 2010 Time:  4:00 PM - 7:30 PM, Exhibit Hall C (Vancouver Convention Centre) / Poster Presentation # 570

About RSV

RSV is the leading cause of lower respiratory tract infections in infants in the United States. It is the most common respiratory infection in infancy or childhood and is associated with both an inpatient and outpatient burden of disease.  Each year RSV hospitalizes up to 125,000 infants in the U.S. with severe RSV infections; it results in an estimated 236,000 hospital outpatient visits; 400,000 emergency room visits and 1.7 million visits to physicians' offices. Approximately one half of all infants are infected with RSV during the first year of life, while nearly all children are infected at least once by the time they reach their second birthday. Children born prematurely as well as those with chronic lung disease (CLD) or congenital heart disease (CHD) are at highest risk for severe disease and hospitalization due to RSV.

About Motavizumab

Motavizumab is an investigational humanized MAb being evaluated for its potential to prevent serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease.  It is currently under review at the U.S. FDA.

About Palivizumab

Palivizumab is the only monoclonal antibody approved by the FDA to help prevent an infectious disease. Palivizumab was approved for use in the United States in 1998, Europe in 1999, and Japan in 2002.  Palivizumab is currently available in 62 countries.  

Palivizumab is a prescription medication that is used to help prevent a serious lung disease caused by respiratory syncytial virus (RSV) in infants and children at high risk. Palivizumab is given as a shot, usually in the thigh muscle, each month during the RSV season. Children who develop an RSV infection while receiving palivizumab should continue the monthly dosing schedule throughout the season.

Palivizumab should not be used in patients with a history of a severe allergic reaction to palivizumab or its ingredients. Cases of severe allergic reactions such as anaphylaxis and other types of hypersensitivity reactions have been reported with palivizumab. These reactions may occur when any dose of palivizumab is given, not just the first one. Very low platelet counts may occur, which may lead to unusual bruising and/or groups of pinpoint red spots found on the skin.

Common side effects may include fever, cold-like symptoms (upper respiratory infection) including runny nose and ear infection, and rash. Other possible side effects include skin reactions around the area where the shot was given (like redness, swelling, warmth or discomfort). In children born with certain types of heart disease, other possible side effects include bluish color of the skin, lips or under fingernails and abnormal heart rhythms. These are not all the possible side effects of palivizumab.

Please see full prescribing information for palivizumab at the company's website: http://www.medimmune.com/about_us_products.aspx. Additional information about the 2010 PAS annual meeting can be found at http://www.pas-meeting.org/2010Vancouver/default.asp

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, a rewarding career to our employees and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MedImmune to Present Data on RSV and Influenza at 2009 American Academy of Pediatrics National Conference & Exhibition
2. MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants
3. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
4. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
5. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
6. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
7. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
8. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
9. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
10. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
11. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... of Australia,s successful biotechnology scientists, Dr ... company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is ... the ASX. Noxopharm is a clinic-ready company with its ... clinical study later this year. ... facing cancer patients - the ability of cancers to become resistant ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals plc ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, ... of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ... (Eastern Daylight Time). As previously announced on ... a definitive merger agreement under which Jazz Pharmaceuticals has ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... "FCPX editors can ... inside of Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... Final Cut Pro X users can now reveal the media of their ...
(Date:6/27/2016)... ... June 27, 2016 , ... A ... revolutionize the emergency ambulance transport experience for the millions of people who require ... has disrupted the taxi industry through the use of technology. Now, SmartEMS has ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... On June ... sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, ... of the city’s history as home to some of the world’s leading providers of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer ... through a fitness app. The fitness app plans to fix the two major problems leading ... a one size fits all type program , They don’t eliminate all the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
Breaking Medicine News(10 mins):